Vision Monday VMail Weekend

August 12 and 13, 2023|www.visionmonday.com



Advertisement

Celebrating Eyewear Pioneer Altina Schinasi

NEW YORK—On August 4, Google’s logo looked a little different. Google often replaces its standard logo with what it calls a Google Doodle—an adaptation of its classic logo to celebrate a holiday, a person, a historical event, a work of art, or anything, really—and the subject of August 4’s Doodle was Altina Schinasi, most well-known as the designer of the Harlequin eyeglass frames. August 4, 2023, marked what would have been Schinasi’s 116th birthday, Google reported, and with the help of her son Terry Sanders, Google created a logo that showcased her iconic design.
Read More


In Case you Missed It - VMail's Top Stories of the Week

U.S. House Committee awaits FTC’s response to requested probe into agency’s regulation of vision insurance market; ECPs’ gross revenue increased, Jobson Tracker says; Iveric Bio gains FDA approval for Izervay; and Vision Expo West to welcome new exhibitors and segments all topped this week’s VMAIL news feed. Click on the headlines below to catch up on anything you might have missed.


No Response Yet From FTC to Congressman's Information Request About Vision Insurance Market


U.S. House Committee on Oversight and Accountability Requests Probe into FTC Regulation of Vision Care Market


The National Average for Gross Revenue at ECP Locations Increased for the Week of July 31–Aug. 6, Jobson’s Latest Practice Performance Tracker Shows


Iveric Bio Gains FDA Approval for Izervay for the Treatment of Geographic Atrophy


Vision Expo West to Welcome New Exhibitors and Segments to Dynamic Show Floor


Insta Pick - Noteworthy Posts From the People We Follow

Editor's Pick

Iveric Bio Gains FDA Approval for Izervay for the Treatment of Geographic Atrophy

TOKYO—Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Izervay, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials, according to the company. "We are thrilled to receive FDA approval of Izervay and to offer a new therapy to physicians and appropriate patients in the U.S.,” said Pravin U. Dugel, MD, president, Iveric Bio, an Astellas company.
Read More




Advertisement


VM's News Quiz

VM's News Quiz for the Week of August 6: ‘Barbie’ Hits a Milestone, an Update on COVID and the FDA Gives a Nod to New Pharma Drug

Did you follow the optical news this week? Take VM’s News Quiz to see how much you know. This week's quiz takes a look at ‘Barbie’ hitting a milestone, an update on COVID and the FDA giving a nod to a new pharma drug.
Click here to take the quiz.


Tweet of the Week

We Share It

This adorable take on a Snellen Chart may not work in the exam room—but it makes a perfect piece of d├ęcor for the dog-loving ECP. You can purchase it in a variety of sizes and colors on Etsy here. #WeShareIt


Optical on Main Street

Indies Have Some Fun With the 'Barbie' Movie

NEW YORK—This week, the "Barbie" movie officially made over $1 billion at the box office. Director Greta Gerwig has become the first and only woman with sole director’s credit for a billion dollar movie, NPR reported, and the film’s popularity has taken the world by storm. On social media in particular, the "Barbie" movie has generated countless trends that users are enjoying—from meme templates to full-hearted reminiscing on childhood memories with Barbie dolls.
Read More

 


Interested in more from VisionMonday and VMail? Click here to subscribe to our other e-newsletters.


VMail Weekend is published by Jobson Medical Information LLC, 395 Hudson Street, New York, NY 10014.

To subscribe to other JMI newsletters or to manage your subscription, click here.